Cytoreductive surgery for malignant peritoneal mesothelioma: importance of patient selection using diagnostic laparoscopy

Japanese Journal of Clinical Oncology 2026 September 24 [Link] Akiyoshi Mizumoto, Nobuyuki Takao, Toru Imagami, Atsushi Hirata, Yasumitsu Oe, Takashi Matsunaga, Akira Sogawa, Byonggu An, Takeshi Togawa Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare malignancy for which cytoreductive surgery (CRS), usually combined with hyperthermic intraperitoneal chemotherapy, is considered in selected patients. However, resectability…

Read More

Low frequency of MTAP co-deletion with CDKN2A in peritoneal mesothelioma suggests an independent diagnostic role for MTAP

Histopathology 2026 September 21 [Link] Andrea Quaranta, Donato Mancini, Concetta Caporusso, Andrea Marzullo, Luigi Vimercati, Cecilia Salzillo, Federica Pezzuto, Fiorella Calabrese, Gabriella Serio Abstract Aims: Loss of MTAP expression by immunohistochemistry (IHC) is widely used as a surrogate for CDKN2A homozygous deletion (HD) in pleural mesothelioma (PM), but its diagnostic value in peritoneal mesothelioma (PeM)…

Read More

Diffuse Pleural Mesothelioma Initially Presenting as Cervical Lymphadenopathy: A Report of a Rare Case

Cureus 2026 August 20 [Link] Kaushik Saha, Sayantika Ghosh, Soumita Poddar Abstract Diffuse mesothelioma is a rare malignant tumor arising from mesothelial cells, showing diffuse involvement of the pleura and having a strong association with asbestos exposure. Cervical lymphadenopathy as the initial presentation of pleural mesothelioma is very unusual to date. We report here such…

Read More

Patient-Derived Organoid Models and Precision HIPEC in Diffuse Malignant Peritoneal Mesothelioma: Modeling Heterogeneity to Address Recurrence

International Journal of Molecular Sciences 2026 September 4 [Link] Eleftherios A Makris, James K Ives, Konstantinos Votanopoulos Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare malignancy for which cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is central to treatment in appropriately selected patients. Recurrence remains common even after complete macroscopic cytoreduction. Current HIPEC…

Read More

BAP1 Loss in Pleural Mesothelioma Is Associated With Reduced Soluble CCL2 in Patient Effusion, Abrogated CCL2-Mediated Monocyte Recruitment In Vitro

JTO Clinical and Research Reports 2026 July 10 [Link] Alistair Nash, Ebony Rouse, Tina Firth, Ian M Dick, Vanessa S Fear, Catherine A Forbes, Amber Louw, Y C Gary Lee, Alec J Redwood, Bruce W Robinson, Jenette Creaney Abstract Objectives: Pleural mesothelioma is an incurable cancer of the cell layer lining the chest wall and…

Read More

Prognostic value of SUVpeak and prognostic nutritional index in patients with pleural mesothelioma treated with platinum-based chemotherapy

Translational Lung Cancer Research 2026 August 31 [Link] Yoshiki Kato, Kosuke Hashimoto, Hisao Imai, Kyoichi Kaira, Reina Ishii, Naohito Hashimoto, Ou Yamaguchi, Atsuto Mouri, Hiroshi Kagamu, Ichiei Kuji Abstract Background: Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis, and reliable prognostic biomarkers are needed to better inform clinical management. We retrospectively investigated the…

Read More

Using an artificial intelligence tool to improve the recognition of pseudoprogression in pleural mesothelioma patients treated with immunotherapy: a case series

Translational Lung Cancer Research 2026 August 31 [Link] Illaa Smesseim, Kalina Chupetlovska, Valerio Pugliese, Jacobus A Burgers, Kevin B W Groot Lipman Abstract Background: Pseudoprogression, defined as initial radiological tumor growth followed by treatment response, can complicate treatment response assessment in patients receiving immunotherapy. In pleural mesothelioma (PM) patients treated with immunotherapy reliable identification of…

Read More

Hyperthermic intrathoracic chemotherapy after cytoreductive surgery in malignant pleural mesothelioma: a single-center retrospective cohort study suggesting increased morbidity without survival benefit

Journal of Thoracic Disease 2026 August 31 [Link] Natalie Baldes, Fabian Doerr, Konstantinos Grapatsas, Balazs Hegedüs, Martin Metzenmacher, Dirk Theegarten, Christian Taube, Martin Schuler, Servet Bölükbas Abstract Background: In the multimodal treatment of pleural mesothelioma (PM), hyperthermic intrathoracic chemotherapy (HITOC) has been investigated as an adjunct to cytoreductive surgery (CRS) to potentially improve local tumor…

Read More

Mesenteric Peritonectomy as the Seventh Peritonectomy Technique in Cytoreductive Surgery for Peritoneal Surface Malignancies: A Propensity Score-Matched Analysis

Annals of Surgical Oncology 2026 September 11 [Link] Francesca Laura Nava, Tommaso Cavalleri, Dario Baratti, Marcello Guaglio, Shigeki Kusamura, Marcello Deraco Abstract Background: Mesenteric involvement represents a major challenge in cytoreductive surgery (CRS) for peritoneal surface malignancies, historically regarded as a relative contraindication to complete cytoreduction. Mesenteric peritonectomy (MP), first described by Deraco et al.…

Read More

Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study

Lung Cancer 2026 November [Link] Jean-Baptiste Assié, Laurent Greillier, Aurelien Gobert, Lionel Falchero, Lise Thibonnier, Matthieu Chasseray, Christine Raynaud, Hugo Picchi, Thierry Chatellier, Romain Corre, Olivier Molinier, Alain Bakebe, Charles Naltet, Fleur-Marie Quillot, Laurene Gavoille, Thomas Pierret, Jean-Marc Dot, Marie Wislez, Marielle Sabatini, Marie Tiercin, Gerard Zalcman, Ophelie Cassuto, Remy Largillier, Anne Madroszyk, Nadia Munsch,…

Read More